SCHEMBL29919476

SCHEMBL29919476

COC(=O)c1cc(=O)n2ccccc2n1.O=C(O)c1cc(=O)n2ccccc2n1

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.54
HPGD P15428 3/20 0.54
MAPT P10636 1/20 0.54
KMT2A Q03164 1/20 0.54
SMN1; SMN2 Q16637 1/20 0.54
ALDH1A1 P00352 4/20 0.51
DAPK3 O43293 1/20 0.51
JAK2 O60674 1/20 0.51
PRKD3 O94806 1/20 0.51
MAP4K4 O95819 1/20 0.51
ABL1 P00519 1/20 0.51
CSF1R P07333 1/20 0.51
RET P07949 1/20 0.51
MET P08581 1/20 0.51
PDGFRA P16234 1/20 0.51
PRKACA P17612 1/20 0.51
LTK P29376 1/20 0.51
GRK5 P34947 1/20 0.51
KDR P35968 1/20 0.51
MAPK8 P45983 1/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL823315 0.95 ALDH1A1 (0.56) KDM4EHPGDMAPTKMT2ASMN1; SMN2
SCHEMBL22499335 0.89 KDM4E (0.57) KDM4EHPGDMAPTKMT2ASMN1; SMN2
Hydrochloric Acid SCHEMBL22499322 0.87 KDM4E (0.56) KDM4EHPGDMAPTKMT2ASMN1; SMN2
SCHEMBL10163632 0.80 KDM4E (0.48) KDM4EHPGDMAPTKMT2ASMN1; SMN2
SCHEMBL8247383 0.80 KDM4E (0.48) KDM4EHPGDMAPTKMT2ASMN1; SMN2
SCHEMBL24691325 0.79 KDM4E (0.56) KDM4EHPGDMAPTKMT2ASMN1; SMN2
SCHEMBL4257194 0.76 ALDH1A1 (0.50) KDM4EHPGDMAPTKMT2ASMN1; SMN2
SCHEMBL29918948 0.76 METTL3 (0.54) KDM4EHPGDMAPTKMT2ASMN1; SMN2
SCHEMBL22499324 0.76 METTL3 (0.57) KDM4EMAPTSMN1; SMN2ALDH1A1METTL3
Lithium Ion SCHEMBL22499045 0.75 METTL3 (0.53) KDM4EHPGDMAPTKMT2ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2022254216-A1 COMBINATION THERAPIES COMPRISING A METTL3 INHIBITOR AND A FURTHER ANTICANCER AGENT STORM THERAPEUTICS LTD (GB) 2022-12-08 WO disclosed
EP-4069694-A1 POLYHETEROCYCLIC COMPOUNDS AS METTL3 INHIBITORS Storm Therapeutics Ltd (GB) 2022-10-12 EP disclosed